Abstract
T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.
Original language | English (US) |
---|---|
Pages (from-to) | 235-248 |
Number of pages | 14 |
Journal | Journal of Immunotoxicology |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2008 |
Keywords
- Antibody
- Leukemia
- Lymphoma
- Receptor
- T-cell
ASJC Scopus subject areas
- Immunology
- Toxicology